Clinical relevance of IL-6 gene rs1800795 polymorphism in patients with ischemic heart disease and chronic heart failure

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Inflammatory cascade contributes to the development of chronic heart failure. In this way, Interleukin-6 measurement in serum is relevant for understanding a course and prognosis in patients with chronic heart failure. Interleukin-6 expression correlates with IL-6 gene rs1800795 polymorphism.

AIM: This study analyzes the research articles about Interleukin-6 effects and IL-6 gene rs1800795 polymorphism in the patients with cardiovascular diseases with ischemic etiology.

MATERIALS AND METHODS: Systematic review and synthesis of findings of independent studies addressing the association between Interleukin-6 measurement and IL-6 gene rs1800795 polymorphism in the patients with coronary artery disease and chronic heart failure, including prognosis assessment.

RESULTS: The articles that were focused on the clinical features and outcomes in the patients with coronary artery disease and chronic heart failure depending on Interleukin-6 level have been analyzed. IL-6 gene rs1800795 polymorphism and its clinical significance have been introduced from the perspective of Interleukin-6 expression, C-reactive protein and lipids level in the blood. The meta-analysis data indicate the correlation between the rs1800795 and risk of coronary artery disease in comparison with homozygotes, as well as additive, recessive and dominant models. This review demonstrates relationship of polymorphism determination to left ventricular functioning, risks of chronic heart failure progression and future cardiovascular diseases.

CONCLUSIONS: The present study demonstrates that IL-6 gene rs1800795 polymorphism can provide comprehensive insights for prognosis assessment in patients with chronic heart failure.

Full Text

Restricted Access

About the authors

Elena V. Khazova

Kazan State Medical University

Author for correspondence.
Email: hazova_elena@mail.ru
ORCID iD: 0000-0001-8050-2892
SPIN-code: 7013-4320
Scopus Author ID: 57205686021
ResearcherId: O-2336-2016

MD, Cand. Sci. (Med.), Аssistant Professor

Russian Federation, Kazan

Renat V. Valiakhmetov

Kazan State Medical University

Email: renat.valiakhmetov.99@bk.ru
ORCID iD: 0000-0001-9984-9677
SPIN-code: 1977-6799
Russian Federation, Kazan

Aigul R. Murzakova

Kazan State Medical University

Email: ajgul.murzakova@yandex.ru
ORCID iD: 0000-0001-9086-183X
SPIN-code: 5346-8847
Russian Federation, Kazan

Olga V. Bulashova

Kazan State Medical University

Email: boulashova@yandex.ru
ORCID iD: 0000-0002-7228-5848
SPIN-code: 4211-2171
Scopus Author ID: 6507198087

MD, Dr. Sci. (Med.), Professor

Russian Federation, Kazan

References

  1. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol. 2001;115(1):3–12. doi: 10.1046/j.1365-2141.2001.03061
  2. Su D, Li Z, Li X, et al. Association between serum interleukin-6 concentration and mortality in patients with coronary artery disease. Mediators Inflamm. 2013;2013:726178. doi: 10.1155/2013/726178
  3. Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145–156. doi: 10.1161/CIRCRESAHA.115.306656
  4. Klimushina MV, Gumanova NG, Kutsenko VA, et al. Association of common polymorphisms in IL-6 and IL6ST genes with levels of inflammatory markers and coronary stenosis. Meta Gene. 2019;21:100593. doi: 10.1016/j.mgene.2019.100593
  5. Haugen E, Gan LM, Isic A, et al. Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients. Exp Clin Cardiol. 2008;13(1):19–24.
  6. Eskandari V, Amirzargar AA, Mahmoudi MJ, et al. Gene expression and levels of IL-6 and TNFα in PBMCs correlate with severity and functional class in patients with chronic heart failure. Ir J Med Sci. 2018;187(2):359–368. doi: 10.1007/s11845-017-1680-2
  7. Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, et al. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019;21(8):965–973. doi: 10.1002/ejhf.1482
  8. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000;275(24):18138–18144. doi: 10.1074/jbc.M000379200
  9. Niu W, Liu Y, Qi Y, et al Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Int J Cardiol. 2012;157(2):243–252. doi: 10.1016/j.ijcard.2011.12.098
  10. Hou H, Wang C, Sun F, et al. Association of interleukin-6 gene polymorphism with coronary artery disease: an updated systematic review and cumulative meta-analysis. Inflamm Res. 2015;64(9):707–720. doi: 10.1007/s00011-015-0850-9
  11. Liu SL, Yin YW, Sun QQ, et al. Genetic polymorphisms of interleukin-6 gene and susceptibility to coronary artery disease in Chinese population: Evidence based on 4582 subjects. Hum Immunol. 2015;76(7):505–510. doi: 10.1016/j.humimm.2015.06.004
  12. Zheng GH, Chen HY, Xiong SQ. Polymorphisms of -174G>C and -572G>C in the interleukin 6 (IL-6) gene and coronary heart disease risk: a meta-analysis of 27 research studies. PLoS One. 2012;7(4):e34839. doi: 10.1371/journal.pone.0034839
  13. Genome [Internet]. Available from: http://www.ensembl.org/Homo_sapiens/Variation/Population?db=core;r=7:22726526-22727526;v=rs1800795;vdb=variation;vf=729516845#373520_table. Accessed: June 21, 2022.
  14. Genotype-Tissue Expression. [Internet]. Available from: https://gtexportal.org/home/snp/rs1800795. Accessed: June 21, 2022.
  15. Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol. 2001;24(11):701–704. doi: 10.1002/clc.4960241103
  16. Sie MP, Sayed-Tabatabaei FA, Oei HH, et al. Interleukin 6 -174 g/c promoter polymorphism and risk of coronary heart disease: results from the rotterdam study and a meta-analysis. Arterioscler Thromb Vasc Biol. 2006;26(1):212–217. doi: 10.1161/01.ATV.0000194099.65024.17
  17. Khidirova LD, Yakhtonov DA, Maximov VN, Zenin SA. The association of genotype and alleles 174G/C (rs1800795) frequency of IL6 gene with clinical data in patients with atrial fibrillation, arterial hypertension in combination with extra-cardiac pathology. International Heart and Vascular Disease Journal. 2019;7(21):12–19. (In Russ.). doi: 10.24412/2311-1623-2019-21-12-19
  18. Shamonina TN, Radaeva OA, Novikova LV, Trofimov VA. Polymorphism of IL-6 genes in arterial hypertension in patients with metabolic syndrome. Fundamental Research. 2014;10(8):1591–1594. (In Russ.)
  19. Shevchenko AV, Golovanova OV, Konenkov VI, et al. Analysis of correlation between il6 gene polymorphism (-174 g /c) and classic risk factors in patients with previous myocardial infarctions. Medical Immunology (Russia). 2009;11(6):557–566. (In Russ.). doi: 10.15789/1563-0625-2009-6-557-566
  20. Di Bona D, Vasto S, Capurso C, et al. Effect of interleukin-6 polymorphisms on human longevity: a systematic review and meta-analysis. Ageing Res Rev. 2009;8(1):36–42. doi: 10.1016/j.arr.2008.09.001
  21. Yin YW, Li JC, Zhang M, et al. Influence of interleukin-6 gene -174G>C polymorphism on development of atherosclerosis: a meta-analysis of 50 studies involving 33,514 subjects. Gene. 2013;529(1):94–103. doi: 10.1016/j.gene.2013.07.074
  22. Smith AJ, D’Aiuto F, Palmen J, et al. Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. Clin Chem. 2008;54(5):841–850. doi: 10.1373/clinchem.2007.098608
  23. Salari N, Mansouri K, Hosseinian-Far A, et al. The effect of polymorphisms (174G> C and 572C> G) on the Interleukin-6 gene in coronary artery disease: a systematic review and meta-analysis. Genes Environ. 2021;43(1):1. doi: 10.1186/s41021-021-00172-8
  24. Humphries SE, Luong LA, Ogg MS, et al. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22(24):2243–2252. doi: 10.1053/euhj.2001.2678
  25. Li L, Li E, Zhang LH, et al. IL-6-174G/C and IL-6-572C/G polymorphisms are associated with increased risk of coronary artery disease. Genet Mol Res. 2015;14(3):8451–8457. doi: 10.4238/2015.July.28.12
  26. Rai H, Colleran R, Cassese S, et al. Association of interleukin 6 -174 G/C polymorphism with coronary artery disease and circulating IL-6 levels: a systematic review and meta-analysis. Inflamm Res. 2021;70(10–12):1075–1087. doi: 10.1007/s00011-021-01505-7
  27. González-Castro TB, Hernández-Díaz Y, Pérez-Hernández N, et al. Interleukin 6 (rs1800795) gene polymorphism is associated with cardiovascular diseases: a meta-analysis of 74 studies with 86,229 subjects. EXCLI J. 2019;18:331–355. doi: 10.17179/excli2019-1248
  28. Tabaei S, Motallebnezhad M, Tabaee SS. Systematic review and meta-analysis of association of polymorphisms in inflammatory cytokine genes with coronary artery disease. Inflamm Res. 2020;69(10):1001–1013. doi: 10.1007/s00011-020-01385-3
  29. Kim SK, Chung JH, Kwon OY. Promoter polymorphism (-174, G/C) of Interleukin-6 and arterial thromboembolic events: a meta-analysis. Med Sci Monit. 2016;22:4345–4353. doi: 10.12659/MSM.901467
  30. Minushkina LO, Chumakova OS, Selezneva ND, et al. Left ventricular hypertrophy development, associated with genetic polymorphism of inflammatory mediators. Russian Journal of Cardiology. 2014;10:23–28. (In Russ.). doi: 10.15829/1560-4071-2014-10-23-28
  31. Bielecka-Dabrowa A, Sakowicz A, Misztal M, et al. Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies. Int J Cardiol. 2016;221:1073–1080. doi: 10.1016/j.ijcard.2016.07.150
  32. Hedayat M, Mahmoudi MJ, Taghvaei M, et al. Tumor Necrosis Factor-Alpha and Interleukin-6 Gene Polymorphisms in Iranian Patients with Ischemic Heart Failure. Avicenna J Med Biotechnol. 2018;10(2):105–109.
  33. Kravchun PG, Kadykova OI, Ryndina NG, et al. Relationship between interleukin-6 gene polymorphism and heart failure in patients with coronary artery disease and obesity. Wiad Lek. 2020;73(8):1637–1640.
  34. Mishra A, Srivastava A, Mittal T, et al. Role of inflammatory gene polymorphisms in left ventricular dysfunction (LVD) susceptibility in coronary artery disease (CAD) patients. Cytokine. 2013;61(3):856–861. doi: 10.1016/j.cyto.2012.12.020
  35. Bielecka-Dabrowa A, Sakowicz A, Pietrucha T, et al. The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction. Sci Rep. 2017;7(1):8974. doi: 10.1038/s41598-017-09564-9

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Khazova E.V., Valiakhmetov R.V., Murzakova A.R., Bulashova O.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 71733 от 08.12.2017.